ASGCT Podcast Network

Lynnea Olivarez, incoming ASGCT Communications Committee chair, will be live at the ASGCT 27th Annual Meeting talking to Society leaders, speakers, and abstract presenters about their contributions and what they're excited about at the Annual Meeting. These bite-sized pods are perfect for your walk between the hotel and convention center or your commute to work during the Annual Meeting.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join host Chris Leidli as he sits down with Emily Walsh Martin, PhD, and Lynnea Olivarez to preview the most intriguing and promising abstracts presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore. Emily and Lynnea share their thoughts on the breathtaking Presidential Symposium before discussing the rest of the program, including clinical implications, the potential impact on rare diseases, and more! Looking for a curated guide through the Annual Meeting? Check out ASGCT's new Session Paths! These six staff-crafted programs provide pathways for some of the most common Annual Meeting attendee profiles: First-time Attendees Cancer Clinical Science Gene Editing Regulatory + Government Affairs Viral Vectors There's still time to register! Join us at the Annual Meeting in Baltimore or from the comfort of your own home with hybrid registration options! Visit https://annualmeeting.asgct.org/register to learn more and register today.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Tune in for an exceptional discussion on chemistry, manufacturing, and controls with Dr. Susan D’Costa, Chief Technical and Commercial Officer at Genezen, a US-based CDMO for viral vectors. "Geek out" with Susan and Emily on the intricacies of defining your CMC strategy and ready yourselves for a tour-de-force of analytical and process development for viral vectors. The future of cell and gene therapy is nearly here! The ASGCT Annual Meeting is less than a month away, and starting on April 22, you can download the abstracts collection to get a sneak peek at the cutting-edge research being presented May 7-11 in Baltimore. Explore the latest breakthroughs and discoveries shaping the field, and don't miss the premier event in cell and gene therapy. Visit www.annualmeeting.asgct.org to learn more and register today! Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join Drs. Timothy Cripe and Marco Davila as they discuss a recent article published in the December issue of Molecular Therapy Oncology by Dr. Davila and colleagues titled, Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Dr. Timothy Cripe: Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children’s Hospital Dr. Marco Davila, Rustum Family Endowed Chair in Translational Research, Senior Vice President and Associate Director for Translational Research, Department of Medicine and Immunology, Roswell Park Comprehensive Cancer Center Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals ASGCT members save $385 on registration rates for the ASGCT Annual Meeting whether you’re attending in person or virtually! Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at annualmeeting.asgct.org. 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join Emily Walsh Martin, PhD for an in-depth interview with Sabrina Mogle, co-founder of RareMoon Consulting. They talk about what drove her to dedicate her career to the orphan drug and advanced therapy space, and how helping clients navigate regulatory conversations on the path from idea to BLA keeps her motivated today. They also discuss her advice for clients in interacting with regulators given the evolving CBER and global regulatory landscape. Do they make it through the whole episode without either providing the standard regulatory wisdom of  “it depends”? Listen to find out! Have you registered for the ASGCT Annual Meeting yet? Meet us in Baltimore, May 7-11, for the only must-attend event in cell and gene therapy. There’s no better place to deep dive in this field than the ASGCT Annual Meeting—you will not find the same breadth or depth of CGT research anywhere in the world. Check out the full program and learn more about the meeting at www.annualmeeting.asgct.org. Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Welcome a special ASGCT Annual Meeting preview hosted by Lynnea Olivarez, member of the ASGCT Communications Committee. Today's guest is Emily Mullin, a staff writer at WIRED who covers biotechnology, medicine, and genetics. Emily is a stalwart on the CGT beat, and today, we're looking ahead to the major topics and themes that will be highlighted at the upcoming ASGCT Annual Meeting. The ASGCT Annual Meeting is the field's flagship event, bringing together stakeholders from academia, industry, regulatory agencies, and more. It's a prime opportunity to exchange research, trends, and the latest in the field. Registration is now open and we hope you'll join us in Baltimore, May 7-11. Find Emily Mullin's work at WIRED.com: https://www.wired.com/author/emily-mullin/ Register today for the ASGCT Annual Meeting: https://annualmeeting.asgct.org/ 'Felicity' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dr. Roland Herzog sits down with Drs. David Schaffer and Adam Schieferecke to discuss a recent article published in the February issue of Molecular Therapy by Drs. Schaffer and Schieferecke and colleagues titled, Evolving membrane-associated accessory protein variants for improved adeno-associated virus production. Read the full article: https://www.cell.com/molecular-therapy-family/molecular-therapy/abstract/S1525-0016(23)00679-2 Dr. Roland Herzog: Editor-in-Chief of Molecular Therapy and Professor of Pediatrics at Indiana University Dr. David Schaffer: Hubbard Howe Jr. Distinguished Professor, Chemical and Biomolecular Engineering, Bioengineering, Molecular and Cell Biology, and the Helen Wills Neuroscience Institute, University of California at Berkeley Dr. Adam Schieferecke: Postdoctoral Scholar, California Institute for Quantitative Biosciences, University of California at Berkeley.  ASGCT members save $385 on registration rates for the Annual Meeting whether you’re attending in person or virtually—that’s a bigger savings than the cost of membership itself, by the way. Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at annualmeeting.asgct.org. Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

A special ASGCT Annual Meeting preview episode and crossover with the Rx for Biotech podcast featuring guest hosts and ASGCT Communications Committee members Chris Leidli and Catherine Gillespie. They interview ASGCT's Molecular Therapy Scientific Editor Rory Bricker-Anthony, PhD, and preview a scientific symposium at the upcoming ASGCT Annual Meeting on the impact of generative AI on cell and gene therapy (CGT), best practices, and real-world applications for communicators. Dr. Bricker-Anthony, a speaker in the session, shares insight into what attendees can learn from the upcoming session, including current tools and applications in AI for CGT communications. Listen now to get a sneak peek of the upcoming symposium at the ASGCT AnnualMeeting and valuable tips for conference attendees. ASGCT Annual Meeting: annualmeeting.asgct.org RX for Biotech Podcast: soundcloud.com/biotechguru Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Today we have a very special guest on The Issue: Federico Mingozzi, PhD. Federico’s first ASGCT podcast could have easily been on Giants of Gene Therapy. Still, we're excited that he could join us for an in-depth chat about his career journey and AAV immunogenicity. Dr. Mingozzi has done seminal work throughout his career in AAV gene therapy, and his 2020 Molecular Therapy review of our current understanding of the immune reaction to these therapies is a must-read for anyone trying to get a handle on the very complicated landscape of immune reactions to viral vectors. Have you registered for the ASGCT Annual Meeting yet? Meet us in Baltimore, May 7-11, for the only must-attend event in cell and gene therapy. There’s no better place to deep dive in this field than the ASGCT Annual Meeting—you will not find the same breadth or depth of CGT research anywhere in the world. Check out the full program and learn more about the meeting at www.annualmeeting.asgct.org. Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join Drs. Paloma Giangrande (Editor-in-Chief of Molecular Therapy Nucleic Acids and Chief Technology Officer at Eleven Therapy) and Maxim Berezovski (Professor of Bioanalytical Chemistry at the University of Ottawa). They will discuss a recent article published in Molecular Therapy Nucleic Acids by Dr. Berezovski and colleagues titled, Discovery of DNA aptamers targeting SARS-CoV-2 nucleocapsid protein and protein-binding epitopes for label-free COVID-19 diagnostics. Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.